LEXINGTON, Mass.--(BUSINESS WIRE)--Aug. 7, 2013--
Synta Pharmaceuticals Corp. (NASDAQ: SNTA) announced today that the
results from an interim survival analysis of the GALAXY-1 trial will be
presented at this year’s Best of ASCO Meetings in Chicago, Los Angeles,
and Boston. GALAXY-1 is a global, randomized Phase 2b/3 study designed
to evaluate the efficacy and safety of the Company’s lead drug
candidate, ganetespib, as second-line treatment for patients with
advanced non-small cell lung adenocarcinoma.
The recent interim analysis for overall survival in GALAXY-1 was first
presented on June 3 during an oral session at the 2013 ASCO Annual
Meeting in Chicago by Dr. Suresh Ramalingam, M.D., Professor, Hematology
& Medical Oncology, and Director, Division of Medical Oncology, of the
Winship Cancer Institute of Emory University. Results showed the
combination of ganetespib and docetaxel improved overall survival and
progression-free survival compared to docetaxel alone, and confirmed
earlier findings of enhanced clinical activity in the prospectively
specified patient population selected last year for further evaluation
in the GALAXY-2 Phase 3 trial. GALAXY-2 is currently enrolling patients,
with results expected in 2014.
The GALAXY-1 results will be presented during the “Non-small Cell
Metastatic Lung Cancer” sessions taking place at:
Best of ASCO Chicago
August 10, 2013, 10:00 – 11:00 AM CDT
Best of ASCO Los Angeles
August 17, 2013, 10:00 – 11:00 AM PDT
Best of ASCO Boston
August 24, 2013, 10:00 – 11:00 AM EDT
Slides discussing the GALAXY-1 results presented at ASCO are available
on the Company’s website at www.syntapharma.com.
Ganetespib, an investigational drug candidate, is a selective inhibitor
of heat shock protein 90 (Hsp90), a molecular chaperone which controls
the folding and activation of a number of client proteins that drive
tumor development and progression. Many solid and hematologic tumors are
dependent on Hsp90 client proteins including proteins involved in
“oncogene addiction” (ALK, HER2, mutant BRAF and EGFR, androgen
receptor, estrogen receptor, JAK2); proteins involved in resistance to
chemotherapy and radiation therapy (ATR, BCL2, BRCA1/2, CDK1/4, CHK1,
survivin, and WEE1); proteins involved in angiogenesis (HIF-1alpha,
VEGFR, PDFGR, and VEGF); and proteins involved in metastasis (MET, RAF,
AKT, MMPs, HIF-1alpha, and IGF-1R). In preclinical models, inhibition of
Hsp90 by ganetespib results in the inactivation, destabilization, and
eventual degradation of these cancer-promoting proteins. Ganetespib is
being evaluated in trials in lung cancer, breast cancer, and other tumor
types. The most common adverse event seen to date has been transient,
mild or moderate diarrhea, which has been manageable with standard
supportive care. Information on these trials can be found at www.clinicaltrials.gov.
About the GALAXY Program
The GALAXY (Ganetespib Assessment in Lung cAncer with docetaXel) program
consists of two randomized trials comparing the combination of
ganetespib and docetaxel versus docetaxel alone in patients with Stage
IIIB/IV NSCLC who have received one prior systemic therapy: a
300-patient Phase 2b/3 trial (GALAXY-1) to determine the patient
population most likely to derive benefit from ganetespib, and a
500-patient confirmatory Phase 3 trial (GALAXY-2). More information
about the GALAXY trials can be found at www.clinicaltrials.gov
(NCT01348126 and NCT01798485).
About Lung Cancer
Lung cancer is the leading cause of cancer-related death in the world,
accounting for nearly 1.4 million deaths in 2008, according to the World
Health Organization. The five-year survival rate for this disease is
approximately 16%; over half of people with lung cancer die within one
year of being diagnosed. In the U.S., the American Cancer Society
estimates that 228,000 cases of lung cancer will be diagnosed in 2013.
Non-small cell adenocarcinoma comprises about 40% of all lung cancer.
About Synta Pharmaceuticals
Synta Pharmaceuticals Corp. is a biopharmaceutical company focused on
discovering, developing, and commercializing small molecule drugs to
extend and enhance the lives of patients with severe medical conditions,
including cancer and chronic inflammatory diseases. Synta has a unique
chemical compound library, an integrated discovery engine, and a diverse
pipeline of clinical- and preclinical-stage drug candidates with
distinct mechanisms of action and novel chemical structures. All Synta
drug candidates were invented by Synta scientists using our compound
library and discovery capabilities. For more information, please visit www.syntapharma.com.
Safe Harbor Statement
This media release may contain forward-looking statements about Synta
Pharmaceuticals Corp. Such forward-looking statements can be identified
by the use of forward-looking terminology such as "will", "would",
"should", "expects", "anticipates", "intends", "plans", "believes",
"may", "estimates", "predicts", "projects", or similar expressions
intended to identify forward-looking statements. Such statements,
including statements relating to the expected timing, developments and
progress of the GALAXY trials, reflect our current views with respect to
future events and are based on assumptions and subject to risks and
uncertainties that could cause actual results to differ materially from
those expressed or implied by such forward-looking statements, including
those described in "Risk Factors" of our Form 10-K for the year ended
December 31, 2012 as filed with the Securities and Exchange Commission.
Synta undertakes no obligation to publicly update forward-looking
statements, whether because of new information, future events or
otherwise, except as required by law.
Source: Synta Pharmaceuticals Corp.
Synta Pharmaceuticals Corp.
Andrea Rabney, 212-600-1494